Protocol Ledger

NCT06577558 · Phase II · RECRUITING

Efficacy and Safety of SR1375 in Adult Patients With CAP

Interventional Phase II clinical trial protocol NCT06577558 sponsored by Shanghai SIMR Biotechnology Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-10 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06577558
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06577558
Protocol FieldVerified Registry Value
NCT IdentifierNCT06577558
Consolidated Lead SponsorShanghai SIMR Biotechnology Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2024-09-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI